Results 41 to 50 of about 18,995 (290)

Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells

Prostate Cancer, 2020
Interleukin-10 (IL10) is best studied for its inhibitory action on immune cells and ability to suppress an antitumour immune response. But IL10 also exerts direct effects on nonimmune cells such as prostate cancer epithelial cells.
Abrar Samiea, Jeff S. J. Yoon, Christopher J. Ong, Amina Zoubeidi, Thomas C. Chamberlain, Alice L.-F. Mui   +5 more
doaj   +1 more source

Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer

Cell Death and Disease, 2022
Androgen receptor (AR) plays an important role in the progression of prostate cancer and has been targeted by castration or AR-antagonists. The emergence of castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT) is ...
Xuanrong Chen, Yi Shao, Wanqing Wei, Shimiao Zhu, Yang Li, Yutong Chen, Hanling Li, Hao Tian, Guijiang Sun, Yuanjie Niu, Zhiqun Shang   +10 more
doaj   +1 more source

Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists and anti-androgen receptor therapy [PDF]

, 2023
Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant

core  

Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor [PDF]

The Journal of Physical Chemistry B, 2019
Androgen receptor (AR) is a steroid hormone nuclear receptor which upon binding its endogenous androgenic ligands (agonists), testosterone and dihydrotestosterone (DHT), alters gene transcription, producing a diverse range of biological effects. Antiandrogens, such as the pharmaceuticals bicalutamide and hydroxyflutamide, act as agonists in the absence
Ettayapuram Ramaprasad Azhagiya Singam, Phum Tachachartvanich, Michele A. La Merrill, Martyn T. Smith, Kathleen A. Durkin   +4 more
openaire   +4 more sources

In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancer [version 4; peer review: 2 approved]

F1000Research
Background: Prostate cancer is a disease that occurs in men aged more than 50 years. In Iraq, 8.89 men per 100,000 population suffer from prostate cancer, with the incidence being 14,016 cases and mortality being 6,367 cases.
Hany Akeel Al-Hussaniy, Mohammed J. AL-Zobaidy, Zahraa S. Al-tameemi   +2 more
doaj   +1 more source

SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. [PDF]

PLoS ONE, 2007
BACKGROUND: Prostate carcinomas are initially dependent on androgens, and castration or androgen antagonists inhibit their growth. After some time though, tumors become resistant and recur with a poor prognosis.
Daniel Compagno, Carole Merle, Aurélie Morin, Cristèle Gilbert, Jacques R R Mathieu, Aline Bozec, Claire Mauduit, Mohammed Benahmed, Florence Cabon   +8 more
doaj   +1 more source

The androgen and progesterone receptors regulate distinct gene networks and cellular functions in decidualizing endometrium

, 2008
Progesterone is indispensable for differentiation of human endometrial stromal cells (HESCs) into decidual cells, a process that critically controls embryo implantation.
Cartwright, JE, Yliheikkila, M., Marius C. Jones, Lam, Eric W.-F., Eric W.-F. Lam, Matti Poutanen, Fusi, L, Luca Fusi, Kim, J. J., Ho, K.-K., Teklenburg, G., Kim, JJ, Poutanen, M, Trew, G, Lavery, S., Cartwright, J. E., Judith E. Cartwright, Cloke, B, Kajihara, T, Geoffrey Trew, Takeshi Kajihara, Huhtinen, K., Jones, M. C., Stuart Lavery, Lam, EW, Jan J. Brosens, Huhtinen, K, Lavery, S, J. Julie Kim, Trew, G., Poutanen, M., Kaisa Huhtinen, Kajihara, T., Brosens, Jan J., Cloke, B., Ho, KK, Teklenburg, G, Jones, MC, Brosens, JJ, Yliheikkilä, M, Maria Yliheikkilä, Gijs Teklenburg, Brianna Cloke, Ka-Kei Ho, Fusi, L.   +44 more
core   +1 more source

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

Molecular Cancer, 2011
Background Hormone therapy is the standard of care for newly diagnosed or recurrent prostate cancers. It uses anti-androgen agents, castration, or both to eliminate cancer promoting effect of testicular androgen. The p53 tumor suppressor controls a major
Packman Kathryn, Xia Mingxuan, Kolinsky Kenneth, Higgins Brian, Tovar Christian, Heimbrook David C, Vassilev Lyubomir T   +6 more
doaj   +1 more source

New Antagonists of the Membrane Androgen Receptor OXER1 from the ZINC Natural Product Database

, 2021
OXER1 (oxoeicosanoid receptor 1) was deorphanized in 1993 and found to be the specific receptor for the arachidonic acid metabolite 5-oxo-ETE. Recently, we have reported that androgen binds to this receptor also, being a membrane androgen receptor ...
Konstantina Kalyvianaki (5601515), Marilena Kampa (3415), Athanasios A. Panagiotopoulos (11620686), Elias Castanas (3426), Stergios A. Pirintsos (11620689), George Notas (3417)   +5 more
core   +1 more source

Steroid Hormones and Endocrine Disruptors: Recent Advances in Receptor–Mediated Actions [PDF]

, 2001
It has been accepted that receptor-mediated action of steroid hormones depends on both the receptor and the hormonal level. The mechanism of transcription by steroid receptors is mediated by cofactors, which function as co-activators or co-repressors,
Indarto, Dono, Izawa, Masao
core